Pedro Barata, MD, MSc, Tulane University School of Medicine, New Orleans, LA, gives an overview of the major highlights in the prostate cancer field from ASCO 2021. Several large-scale Phase III trials in the advanced prostate cancer setting were presented at this year’s meeting. Dr Barata comments on the much-anticipated results of the VISION trial (NCT03511664) assessing the addition of 177Lu-PSMA-617 to standard of care (SOC) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The trial was the first to demonstrate a statistically significant improvement in overall survival with a PSMA-targeted agent in this patient population and may be practice-changing. Dr Barata also discusses the implications of the first results from the Phase III PEACE-1 trial (NCT01957436) of abiraterone combined with SOC with or without local radiotherapy in men with mCRPC. The PEACE III (NCT02194842) trial assessing the upfront combination of enzalutamide and radium-223, and the SWOG S1216 trial (NCT01809691) of androgen deprivation therapy plus TAK-700 are also highlighted. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.